XKRX
174900
Market cap142mUSD
Jun 04, Last price
12,780.00KRW
1D
-2.96%
1Q
-1.39%
IPO
-14.94%
Name
AbClon Inc
Chart & Performance
P/E
—
P/S
83.85
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.54%
Rev. gr., 5y
-30.45%
Revenues
2.34b
-24.10%
Net income
-16.30b
L+27.70%
CFO
-14.39b
L+51.78%
Profile
AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 2,339,824 -24.10% | 3,082,804 -9.50% | 3,406,446 12.87% | |||
Cost of revenue | 15,568,428 | 12,437,243 | 10,428,101 | |||
Unusual Expense (Income) | ||||||
NOPBT | (13,228,604) | (9,354,439) | (7,021,656) | |||
NOPBT Margin | ||||||
Operating Taxes | 10,953 | (1,095,307) | ||||
Tax Rate | ||||||
NOPAT | (13,228,604) | (9,365,392) | (5,926,349) | |||
Net income | (16,301,552) 27.70% | (12,765,642) 37.95% | (9,253,794) -9.61% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 17,000 | 85,000 | 70,000 | |||
BB yield | -0.01% | -0.04% | -0.04% | |||
| Debt | ||||||
Debt current | 17,241,934 | 12,576,191 | 7,149,341 | |||
Long-term debt | 160,062 | 100,423 | 4,807,889 | |||
Deferred revenue | ||||||
Other long-term liabilities | 660,957 | 565,226 | 4,094,829 | |||
Net debt | (4,460,928) | (4,821,460) | (12,182,337) | |||
| Cash flow | ||||||
Cash from operating activities | (14,394,378) | (9,483,894) | (7,491,984) | |||
CAPEX | (166,858) | (45,942) | (89,707) | |||
Cash from investing activities | 2,074,751 | 13,551,153 | (9,463,441) | |||
Cash from financing activities | 18,843,263 | 2,891,814 | 21,486,164 | |||
FCF | (12,638,292) | (7,683,521) | (15,750,295) | |||
| Balance | ||||||
Cash | 21,862,924 | 17,498,074 | 24,139,567 | |||
Long term investments | ||||||
Excess cash | 21,745,933 | 17,343,934 | 23,969,245 | |||
Stockholders' equity | (63,728,457) | (48,167,733) | (24,633,613) | |||
Invested Capital | 111,046,403 | 88,566,295 | 77,091,250 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 17,303 | 15,365 | 15,121 | |||
Price | 14,120.00 -4.72% | 14,820.00 15.78% | 12,800.00 -27.68% | |||
Market cap | 244,316,849 7.30% | 227,705,625 17.65% | 193,543,398 -28.44% | |||
EV | 240,298,002 | 223,527,611 | 181,955,415 | |||
EBITDA | (11,638,011) | (7,670,183) | (5,504,576) | |||
EV/EBITDA | ||||||
Interest | 900,057 | 1,350,399 | 489,586 | |||
Interest/NOPBT | ||||||